標題: Titlebook: Antibodies; Volume 2: Novel Tech G. Subramanian Book 2004 Springer Science+Business Media New York 2004 HIV.cancer.cancer therapy.cells.dev [打印本頁] 作者: Intimidate 時間: 2025-3-21 18:32
書目名稱Antibodies影響因子(影響力)
書目名稱Antibodies影響因子(影響力)學科排名
書目名稱Antibodies網絡公開度
書目名稱Antibodies網絡公開度學科排名
書目名稱Antibodies被引頻次
書目名稱Antibodies被引頻次學科排名
書目名稱Antibodies年度引用
書目名稱Antibodies年度引用學科排名
書目名稱Antibodies讀者反饋
書目名稱Antibodies讀者反饋學科排名
作者: electrolyte 時間: 2025-3-21 21:37 作者: Hdl348 時間: 2025-3-22 01:58
Intrabodies: Development and Application in Functional Genomics and Therapy,is to interfere with their expression (.). Approaches such as gene knockout, antisense oligonucleotide or RNA interference (RNAi) are currently used to study gene and protein function and to validate candidate drug targets by analysing the effects of their deletion. One limitation of all these techn作者: 上坡 時間: 2025-3-22 07:29
Expression of Recombinant Antibodies by Tumour Cells: On Road to Anti-Tumour Therapy, represent exciting tools for the targeted delivery of drugs, enzymes, and toxins at the site of the tumours. In addition, antibody-based radio-immunotherapy (RIT) should make it possible to circumvent the limitation of the treatment of solid tumours with antibodies due to the weak penetration of in作者: Anthrp 時間: 2025-3-22 09:48
Regine Witkowski,Falko H. Herrmann genetic engineering has allowed the conversion of existing mouse monoclonal antibodies into chimeric mouse-human antibodies, and humanised molecules where only the complementarity-determining regions (CDR) are of murine origin (.). To date, 13 therapeutic antibodies have obtained regulatory approva作者: 流浪 時間: 2025-3-22 13:29 作者: Mutter 時間: 2025-3-22 20:23 作者: intuition 時間: 2025-3-22 22:53 作者: minion 時間: 2025-3-23 04:20 作者: 態(tài)度暖昧 時間: 2025-3-23 08:47 作者: 散布 時間: 2025-3-23 12:57
http://image.papertrans.cn/a/image/158460.jpg作者: 發(fā)炎 時間: 2025-3-23 14:59
https://doi.org/10.1007/978-1-4419-8877-5HIV; cancer; cancer therapy; cells; development; future; immunotherapy; kinetics; macrophages; manufacturing; 作者: Ganglion-Cyst 時間: 2025-3-23 20:03 作者: Decongestant 時間: 2025-3-23 22:51 作者: 格子架 時間: 2025-3-24 02:53 作者: AUGUR 時間: 2025-3-24 10:25 作者: conifer 時間: 2025-3-24 12:07 作者: 心胸狹窄 時間: 2025-3-24 16:30
Einführung in die klinische Neurophysiologiet monkeys from infections mediated by the HIV-1 envelope glycoprotein (Env) in a concentration dependent manner (.; .; .; .; .; .; .; .; .; .; .). In some of these experiments human monoclonal antibodies (hmAbs) were used that exhibit potent and broad HTV neutralizing activity in vitro (.; .; .). Re作者: DEMUR 時間: 2025-3-24 20:05 作者: AVOID 時間: 2025-3-25 02:17
Einführung in die kombinatorische Topologie by the press, however did not keep theirs promise. Indeed, apart OKT3 a mouse mAb directed against the T lymphocyte CD3 molecule, the first to get US and European approvals in the prevention of organ rejection in 1986, several trials conducted with other mAbs did not show significant results. These作者: Analogy 時間: 2025-3-25 07:04
https://doi.org/10.1007/978-3-322-85526-8with thousands of new potential drug targets, most of which function in intracellular compartments (.; .). This fact opens new perspectives for therapy of human diseases; however, it also demands reliable approaches for understanding the role and the function of these new genes and proteins (functio作者: 信徒 時間: 2025-3-25 07:45 作者: avenge 時間: 2025-3-25 15:35 作者: 閑聊 時間: 2025-3-25 16:18
Einführung in die lineare Algebrall Processor able to generate large number of clinical grade Monocyte-derived Activated Killer cells (MAK.). These macrophages were armed with a bispecific antibody (MDX-H210, Medarex Inc., Keler, 1997), recognizing CD64/FcγRl (on the MAK cell) and the oncoprotein HER-2/neu on tumour cell and presen作者: CON 時間: 2025-3-25 21:04
Einführung in die lineare Algebra mAb to be approved for a clinical use was a murine antibody (OKT3, or Muromomab) ., it became increasingly obvious that only mAbs with a decreased immunogenicity could be used for repeated injections in Humans. The generation of a Human Anti-Mouse Antibody (HAMA) response when murine mAbs are infus作者: biopsy 時間: 2025-3-26 00:24
Antitumor Antibodies: From Research to Clinic,ants of growing hybridoma cells coming from 150 different somatic fusions of spleen cells from mice immunized with different immunogens and protocols, were screened for specific reactivity on tumor cells. Only 45 monoclonal antibodies were selected for basic researches and clinical applications.作者: verdict 時間: 2025-3-26 06:31 作者: GUMP 時間: 2025-3-26 10:08 作者: Pert敏捷 時間: 2025-3-26 13:53 作者: bacteria 時間: 2025-3-26 19:25
Transgenic Technology for Monoclonal Antibody Production,nature of monoclonal antibody therapies, and the relatively large size of the monoclonal antibody molecules dictate that the production requirements for many of these therapeutic monoclonal antibody products will be 100 kilograms or more per year. It is widely acknowledged that there is currently a 作者: 自戀 時間: 2025-3-26 23:20
,Generation, Engineering and Production of Human Antibodies Using Hucal?,mmunized mice (.). The technique was rapidly and widely adopted and has provided an enormous repertoire of useful research reagents (.). On the other hand, these antibodies have had limited success in human therapy (.). One reason is that murine antibodies often cause immune response in humans and l作者: 漂浮 時間: 2025-3-27 04:01 作者: helper-T-cells 時間: 2025-3-27 06:29
Approaches to Devise Antibody Purification Processes by Chromatography,ed and purified protein in number and quantity. New potential applications of antibodies in their native form or various engineered constructs actually continue to stimulate therapeutic areas. Expected high dosage levels imply that their purity has to meet stringent requirements. It means also that 作者: 世俗 時間: 2025-3-27 12:24 作者: Intrepid 時間: 2025-3-27 15:10 作者: 步履蹣跚 時間: 2025-3-27 17:58 作者: condemn 時間: 2025-3-28 01:05 作者: 和藹 時間: 2025-3-28 03:53
Expression of Recombinant Antibodies by Tumour Cells: On Road to Anti-Tumour Therapy,ir ability to activate potent effector functions makes them an ideal tool for cancer therapy. Depending on their classes and subclasses, antibodies can activate complement and/or trigger effector functions such as Antibody-Dependent Cell Cytotoxicity (ADCC) following interactions with the receptors 作者: cutlery 時間: 2025-3-28 10:17 作者: Blood-Clot 時間: 2025-3-28 13:08 作者: 忙碌 時間: 2025-3-28 17:24
Future Prospects in Antibody Engineering and Therapy, mAb to be approved for a clinical use was a murine antibody (OKT3, or Muromomab) ., it became increasingly obvious that only mAbs with a decreased immunogenicity could be used for repeated injections in Humans. The generation of a Human Anti-Mouse Antibody (HAMA) response when murine mAbs are infus作者: 怒目而視 時間: 2025-3-28 21:51 作者: 中國紀念碑 時間: 2025-3-28 23:46 作者: Pituitary-Gland 時間: 2025-3-29 05:11 作者: 厭倦嗎你 時間: 2025-3-29 08:47 作者: Manifest 時間: 2025-3-29 12:31
Antibodies, a Potent Tool to Target Genes into Designated Cells and Tissues, poor effects were mainly due to generation of anti-murine Abs by the patients, hindering the efficacy of the treatment. Moreover, rodent IgG Abs injected to patients have half-life of less than 20 hrs compared to several days for human Igs.作者: heterogeneous 時間: 2025-3-29 15:48 作者: BINGE 時間: 2025-3-29 21:36
,Gef??tumoren und Gef??mi?bildungen,sylation and measuring its biological effects have revolutionized the discipline of “glycobiology”. Thus, extremely subtle alterations in glycoproteins can now be detected, and appropriate modifications brought about which were nearly impossible 20 years ago.作者: NOMAD 時間: 2025-3-30 02:16
Die freien Gruppen und ihre Faktorgruppen, studies has been on efficacy in clinical conditions or in animal models of human cancers, and little consideration has been given to the effects of the combination of these antibodies and radiation therapy.作者: 祝賀 時間: 2025-3-30 06:19
